Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Purchased by CenterBook Partners LP

CenterBook Partners LP increased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 273.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 1,327 shares of the medical research company's stock after purchasing an additional 972 shares during the period. CenterBook Partners LP's holdings in Thermo Fisher Scientific were worth $690,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in TMO. Barrett & Company Inc. acquired a new position in shares of Thermo Fisher Scientific in the fourth quarter worth $28,000. FPC Investment Advisory Inc. acquired a new position in shares of Thermo Fisher Scientific during the fourth quarter worth about $28,000. Missouri Trust & Investment Co acquired a new stake in Thermo Fisher Scientific in the fourth quarter valued at approximately $29,000. Pillar Financial Advisors LLC purchased a new position in Thermo Fisher Scientific in the fourth quarter worth approximately $29,000. Finally, Endeavor Private Wealth Inc. purchased a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at approximately $30,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, SVP Michael A. Boxer sold 3,775 shares of the company's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the completion of the transaction, the senior vice president now owns 10,816 shares of the company's stock, valued at approximately $5,759,736.32. This represents a 25.87 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Stephen Williamson sold 9,825 shares of the company's stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $5,753,421.75. Following the sale, the chief financial officer now owns 27,296 shares of the company's stock, valued at $15,984,264.64. This represents a 26.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 23,900 shares of company stock worth $13,106,062. Corporate insiders own 0.34% of the company's stock.

Remove Ads

Thermo Fisher Scientific Price Performance

NYSE TMO traded down $4.10 during mid-day trading on Wednesday, hitting $436.90. The stock had a trading volume of 1,814,646 shares, compared to its average volume of 1,707,958. The company has a 50 day simple moving average of $505.28 and a 200 day simple moving average of $536.95. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. The company has a market cap of $164.93 billion, a price-to-earnings ratio of 26.43, a P/E/G ratio of 2.99 and a beta of 0.86. Thermo Fisher Scientific Inc. has a 52-week low of $409.85 and a 52-week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, beating analysts' consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. Equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, April 15th. Investors of record on Friday, March 14th were paid a $0.43 dividend. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.39. The ex-dividend date was Friday, March 14th. This represents a $1.72 annualized dividend and a yield of 0.39%. Thermo Fisher Scientific's payout ratio is presently 10.41%.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on TMO shares. UBS Group boosted their target price on shares of Thermo Fisher Scientific from $700.00 to $715.00 and gave the stock a "buy" rating in a research note on Friday, January 31st. Morgan Stanley increased their price objective on Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an "overweight" rating in a report on Friday, January 31st. Sanford C. Bernstein upgraded Thermo Fisher Scientific from a "market perform" rating to an "outperform" rating and set a $630.00 target price for the company in a research note on Friday, January 10th. Scotiabank raised their price objective on shares of Thermo Fisher Scientific from $605.00 to $650.00 and gave the stock a "sector perform" rating in a report on Monday, February 3rd. Finally, Wells Fargo & Company upped their target price on shares of Thermo Fisher Scientific from $660.00 to $680.00 and gave the company an "overweight" rating in a report on Friday, January 31st. Four investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. Based on data from MarketBeat, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and an average price target of $647.43.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.